CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Sees Significant Increase in Short Interest

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) was the target of a large increase in short interest in May. As of May 29th, there was short interest totaling 138,254 shares, an increase of 161.2% from the May 14th total of 52,933 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average trading volume of 1,432,012 shares, the days-to-cover ratio is currently 0.1 days.

CSL Stock Down 0.4%

Shares of CSLLY opened at $19.06 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.57 and a quick ratio of 1.15. The business’s 50 day moving average price is $20.66 and its 200-day moving average price is $39.97. CSL has a 52 week low of $16.01 and a 52 week high of $44.86.

Wall Street Analyst Weigh In

Several research firms have weighed in on CSLLY. Citigroup cut CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Canaccord Genuity Group cut CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Jefferies Financial Group cut CSL from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 29th. Finally, Zacks Research cut CSL from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

CSL Company Profile

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.